News Center
For the third consecutive year, Livzon Group's information disclosure has received high recognition.
Release time:
2024-10-14
Recently, the Shenzhen Stock Exchange (hereinafter referred to as "SZSE") announced the evaluation results of information disclosure work for listed companies on the Shenzhen Main Board for the 2023-2024 fiscal year. Livzon Pharmaceutical Group was awarded an A grade (the highest), marking the fifth consecutive year that Livzon has received this recognition. This is also a high affirmation from the SZSE regarding the company's information disclosure quality, investor relations, and sustainable development efforts.
The assessment results show that among the 2,807 listed companies participating in the assessment on the Shenzhen market, 487 companies received an A grade, accounting for 17.35% of the total number of participating listed companies. The SZSE's information disclosure work evaluation aims to strengthen the supervision of listed companies' information disclosure, promote high-quality development of listed companies, and provide a comprehensive assessment of the quality of information disclosure and related work of listed companies on the Shenzhen market. It covers multiple dimensions, including information disclosure quality, investor relations management, social responsibility fulfillment, internal governance, and innovation in information disclosure management, serving as an important indicator for measuring the governance level and information disclosure quality of listed companies.
Livzon Pharmaceutical Group has consistently improved its corporate governance level, strictly adhering to the relevant requirements of laws and regulations, the China Securities Regulatory Commission, and normative documents from the Shenzhen Stock Exchange. The company diligently fulfills its information disclosure obligations, continuously enhancing the breadth and depth of information disclosure. Through various innovative channels, it actively communicates and engages with investors, increasing the disclosure of information related to social responsibility and risk prevention. Livzon has published ESG reports for eight consecutive years and has fully integrated ESG concepts into its production and operational processes, continuously improving its sustainable development level. In 2024, Livzon was awarded the highest AAA rating in the MSCI ESG ratings.
In the future, Livzon Pharmaceutical Group will continue to uphold the development philosophy of "returning to investors," continuously improving the quality of information disclosure, standardizing operations, and enhancing corporate governance levels to create more value for shareholders, customers, and society.
Related Information